On February 25, 2025, Lixte Biotechnology announced the addition of the Lurie Cancer Center as a second site for a clinical trial using its compound LB-100 with GSK's Dostarlimab for treating ovarian clear cell cancer, with patient recruitment underway and the first patient dosed.